Report
Geir Hiller Holom
EUR 87.39 For Business Accounts Only

Gentian Diagnostics (Buy, TP: NOK53.00) - Record-high sales

While Gentian enjoyed a currency tailwind, it continued to report steady growth and Q2 saw record-high sales. Its NT-proBNP efforts are still progressing, but the outcome remains uncertain. We have made limited estimate revisions and continue to consider Gentian attractively valued. We reiterate our BUY and NOK53 target price.
Underlying
Gentian Diagnostics

Gentian Diagnostics AS is a Norway-based company within health care sector. It develops and manufactures in vitro diagnostic products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company's product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on most major clinical chemistry analysers; canine CRP, which is an acute phase protein synthesized in the liver that is used for diagnosis and treatment of inflammatory diseases in dogs; NGAL Immunoassay, which is a particle-enhanced turbidimetric immunoassay (PETIA) for in vitro diagnostic testing of neutrophil gelatinase-associated lipocalin (NGAL) in human urine and plasma samples; and cystatin C immunoassay, which is a PETIA for use on a range of clinical chemistry analyzers. The Company operates domestically, as well as in China and the Unites States.

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Geir Hiller Holom

Other Reports on these Companies
Other Reports from DnB Markets

ResearchPool Subscriptions

Get the most out of your insights

Get in touch